Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
arcticnovartis
Wed, 11/27/2024 – 07:19
Read more about Novartis Kisqali® receives European Comm…
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
arcticnovartis
Mon, 11/25/2024 – 07:19
Read more about Novartis highlights new 96-wee…
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
arcticnovartis
Thu, 11/21/2024 – 07:04
Read more about Novartis upgrades mid-term guidance and highlights deep pipeline in core th…
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
arcticnovartis
Thu, 11/21/2024 – 07:04
Read more about Novartis upgrades mid-term guidance and highlights deep pipeline in core th…
Novartis ranks first in 2024 Access to Medicine Index
arcticnovartis
Tue, 11/19/2024 – 14:04
Read more about Novartis ranks first in 2024 Access to Medicine Index
The Index spotlights Novartis leadership in research and development…
Novartis ranks first in 2024 Access to Medicine Index
arcticnovartis
Tue, 11/19/2024 – 14:04
Read more about Novartis ranks first in 2024 Access to Medicine Index
The Index spotlights Novartis leadership in research and development…
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
arcticnovartis
Tue, 10/29/2024 – 20:14
Read more about Novartis Scemblix® FDA approved in newly diagnosed CML, offeri…
Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben
arcticnovartis
Tue, 10/29/2024 – 07:02
Read more…
Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben
arcticnovartis
Tue, 10/29/2024 – 07:02
Read more…
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
arcticnovartis
Tue, 10/29/2024 – 07:02
Read more about Novartis continues strong momentu…
